DAFNA Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

DAFNA Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-106,810	Closed	-$395K	–	84
2017 Q4	$395K	Sell	106,810 -10,500	-9%	-$43K	0.21%	62
2017 Q3	$480K	Hold	117,310	–	–	0.3%	55
2017 Q2	$436K	Sell	117,310 -67,949	-37%	-$270K	0.31%	55
2017 Q1	$767K	Buy	+185,259	New	+$779K	0.65%	46
2016 Q3	–	Sell	-29,167	Closed	-$165K	–	101
2016 Q2	$165K	Buy	+29,167	New	+$198K	0.13%	82
2015 Q4	–	Sell	-6,030	Closed	-$99K	–	89
2015 Q3	$99K	Hold	6,030	–	–	0.1%	79
2015 Q2	$135K	Buy	+6,030	New	+$95.4K	0.11%	69
2014 Q4	–	Sell	-35,829	Closed	-$413K	–	70
2014 Q3	$413K	Buy	+35,829	New	+$547K	0.42%	39

DAFNA Capital Management's CASC Position: Q1 2018 in Review

DAFNA Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 106,810 shares — an estimated $395K sold.

DAFNA Capital Management first reported a position in CASC in Q3 2014 and held it in 8 quarters. The position peaked at $767K in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

DAFNA Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
DAFNA Capital Management sold 106,810 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $395K.
DAFNA Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 8 quarters.
DAFNA Capital Management's Cascadian Therapeutics, Inc. position peaked at $767K in Q1 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.